Clinical trialNCT07218926RecruitingPhase 3Interventional

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

SponsorGlaxoSmithKlineEnrollment450Gastrointestinal Neoplasms

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib. Participants whose disease worsens after receiving sunitinib in this study may cross over to receive GSK6042981, at investigator's discretion and if additional eligibility criteria are met.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

124 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Gsk Investigational Site
Garran, Australian Capital Territory, Australia
Desmond Yip
Recruiting
Gsk Investigational Site
Westmead, New South Wales, Australia
Ka Yeung Mark Wong
Recruiting
Gsk Investigational Site
Melbourne, Victoria, Australia
John Zalcberg
Recruiting

Belgium

Gsk Investigational Site
Leuven, Belgium
Patrick Schoffski
Recruiting

Brazil

Gsk Investigational Site
Barretos, São Paulo, Brazil
Leticia Costa
Recruiting
Gsk Investigational Site
São Caetano do Sul, São Paulo, Brazil
Daniel Cubero
Recruiting
Gsk Investigational Site
Porto Alegre, Brazil
Andreas Lutz
Recruiting
Gsk Investigational Site
Recife, Brazil
Marcelo Ramos Tejo Ramos Tejo Salgado
Recruiting
Gsk Investigational Site
Vitória, Brazil
GLAUCIO BERTOLLO
Recruiting

Canada

Gsk Investigational Site
Calgary, Alberta, Canada
Xiaolan Feng
Recruiting
Gsk Investigational Site
Toronto, Ontario, Canada
Albiruni Ryan Ryan Abdul Abdul Razak
Recruiting
Gsk Investigational Site
Montreal, Quebec, Canada
Jonathan Noujaim
Recruiting

China

Gsk Investigational Site
Shanghai, Shanghai Municipality, China
Ye Zhou
Recruiting
Gsk Investigational Site
Beijing, China
Jian Li
Recruiting
Gsk Investigational Site
Hangzhou, China
Yu Zheng
Recruiting
Gsk Investigational Site
Jinan, China
Lei Cong
Recruiting
Gsk Investigational Site
Shanghai, China
Ming Wang
Recruiting
Gsk Investigational Site
Wuhan, China
Kai-Xiong Tao
Recruiting

France

Gsk Investigational Site
Angers, France
pierre kubicek
Recruiting
Gsk Investigational Site
Bordeaux, France
Antoine Italiano
Recruiting
Gsk Investigational Site
Lille, France
Loic Lebellec
Recruiting
Gsk Investigational Site
Lyon, France
Jean-Yves Blay
Recruiting
Gsk Investigational Site
Marseille, France
Florence Duffaud
Recruiting
Gsk Investigational Site
Saint-Herblain, France
Emmanuelle Bompas
Recruiting
Gsk Investigational Site
Toulouse, France
Thibaud Valentin
Recruiting
Gsk Investigational Site
Villejuif, France
axel LE CESNE
Recruiting

Germany

Gsk Investigational Site
Berlin, Germany
Peter Reichardt
Recruiting
Gsk Investigational Site
Essen, Germany
Sebastian Bauer
Recruiting
Gsk Investigational Site
Mannheim, Germany
Bernd Kasper
Recruiting

Hungary

Gsk Investigational Site
Pécs, Hungary
László Mangel
Recruiting

Italy

Gsk Investigational Site
Meldola, FC, Italy
Lorena Gurrieri
Recruiting
Gsk Investigational Site
Rozzano MI, Lombardy, Italy
Alexia Bertuzzi
Recruiting
Gsk Investigational Site
Bari, Italy
Michele Guida
Recruiting
Gsk Investigational Site
Candiolo, Italy
Sandra Aliberti
Recruiting
Gsk Investigational Site
Genova, Italy
Danila Comandini
Recruiting
Gsk Investigational Site
Milan, Italy
Roberta Giovanna Sanfilippo
Recruiting
Gsk Investigational Site
Milan, Italy
Elena Rosa Fumagalli
Recruiting
Gsk Investigational Site
Palermo, Italy
Giuseppe Badalamenti
Recruiting
Gsk Investigational Site
Roma, Italy
Bruno Vincenzi
Recruiting

Japan

Gsk Investigational Site
Chiba, Japan
Saori Mishima
Recruiting

84 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

IDRX-42Sunitinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 3 Dec 2025
Primary completion: 30 May 2028
Completion: 29 Nov 2030
Last update posted: 12 Jun 2026
Registered enrollment: 450
Registry id: NCT07218926

Cross-registrations

EU-CTR / CTIS (EudraCT)2025-522229-37-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.